{'fraction_non_alphanumeric': 0.02679528403001072, 'fraction_numerical': 0.010718113612004287, 'mean_word_length': 5.768115942028985, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Postmortem Study to Compare Agonist and Antagonist 5‐HT1A Receptor‐binding Sites in Alzheimer's Disease

Positron emission tomography (PET) imaging using 5‐HT1A receptor radioligands shows a decreased expression of this serotonin receptor in the hippocampus of patients with Alzheimer's disease (AD) at advanced stages. However, previous 5‐HT1A receptor radioligands used in human imaging were antagonists, thought to bind to 5‐HT1A receptors in different functional states (i.e., both the one which displays high affinity for agonists and is thought to mediate receptor activation, as well as the functional state which has low affinity for agonists). Comparing the PET imaging obtained using an agonist radioligand, which binds selectively to the functional state of the receptors, with the PET imaging obtained using an antagonist radioligand would therefore provide original information on 5‐HT1A receptor impairment during AD.